BRIEF-Ultragenyx: Long-Term UX111 Data Shows Sustained CSF-HS Reductions, Multi-Domain Gains In Children With Sanfilippo Syndrome (Mps Iiia)Feb 3 (Reuters) - Ultragenyx Pharmaceutical Inc RARE.O:
ULTRAGENYX ANNOUNCES POSITIVE LONGER-TERM DATA DEMONSTRATING TREATMENT WITH UX111 GENE THERAPY RESULTS IN SUSTAINED, SIGNIFICANT REDUCTIONS IN CSF-HS AND CONTINUED MEANINGFUL IMPROVEMENTS IN CLINICAL FUNCTION ACROSS MULTIPLE DEVELOPMENTAL DOMAINS IN CHILDREN WITH SANFILIPPO SYNDROME (MPS IIIA)
ULTRAGENYX PHARMACEUTICAL INC - BLA RESUBMITTED TO FDA, SIX-MONTH REVIEW EXPECTED
ULTRAGENYX PHARMACEUTICAL INC - RESULTS SHOW SUBSTANTIAL BIOMARKER IMPROVEMENTS AND FUNCTIONAL BENEFITS
ULTRAGENYX PHARMACEUTICAL INC - UX111 WELL TOLERATED ACROSS ALL DOSES
Source text: ID:nGNX5NdJ2w
Further company coverage: RARE.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments